Neurosense Therapeutics is trading at $0.51 (+5.6%) in pre-market, extending an after-hours rebound from a sharp multi-day selloff that saw shares close at $0.48 on July 29, 2026.
- The price action is being attributed to bargain-hunting following recent biotech sector weakness and concerns regarding Nasdaq compliance.
- There have been no new company-specific announcements or fundamental catalysts to account for the move.
- The stock is currently recovering from a period of significant downward pressure that pushed shares to recent lows.